Follistatin: Myostatin Blockade and the Injectable Gap

At a Glance

Follistatin has the most impressive preclinical story in this batch and the widest gap between that story and anything a person can buy. Transgenic mice overexpressing follistatin in skeletal muscle develop dramatic increases in muscle mass, comparable to myostatin knockouts (Lee 2001). A follistatin gene delivered by adeno-associated virus into monkey quadriceps produced pronounced and durable increases in muscle size and strength (Kota 2009). Those are real results, and they are why the word follistatin carries the weight it does.

The honest verdict requires separating two completely different interventions. Gene therapy puts the follistatin gene inside muscle fibres, where it produces protein continuously for months. That has been tested in humans, in two small trials, with modest and contested functional results. Injectable follistatin protein, which is what the grey market sells, delivers a brief systemic dose of a large glycoprotein and has never been tested in a human trial of any kind.

The community’s own aggregated reports say the quiet part out loud: expectations set by the animal data are routinely disappointed by injectable protein, and many users describe minimal or no noticeable effect. That alignment between mechanism, evidence and experience is unusual in this field, and it is worth taking seriously.

How it works

Myostatin (GDF-8) is a TGF-β family member that restrains skeletal muscle mass. Its C-terminal dimer signals through activin type II receptors, mainly ActRIIB. The decisive mechanistic study purified myostatin, showed the C-terminal dimer binds ActRIIB and, less strongly, ActRIIA, and demonstrated that this binding is inhibited by follistatin and, at higher concentrations, by the myostatin propeptide. Transgenic mice expressing high levels of the propeptide, follistatin, or a dominant-negative ActRIIB under a muscle-specific promoter all showed dramatic increases in muscle mass comparable to myostatin knockout mice (Lee 2001).

Two features of follistatin matter for anyone reading claims about it:

• It is not myostatin-selective. Follistatin’s primary identity is as an activin-binding protein. Activins have roles in reproduction, inflammation, wound repair and glucose metabolism, so blocking them has consequences beyond muscle. In humans, circulating follistatin falls after oral or intravenous glucose, and falls by 22 to 33% after Roux-en-Y gastric bypass or sleeve gastrectomy, with the three-month change predicting improvements in glucose, insulin, HOMA-IR and HbA1c at six months (Perakakis 2019).
• Isoform and delivery determine where it acts. FST-288 binds cell surfaces tightly, FST-315 circulates, and FST-344 is the construct used in gene therapy precisely because it affects skeletal muscle with minimal effects on non-muscle cells (Kota 2009).

That second point is also the pharmacological problem with injected protein. Follistatin is a glycoprotein, not a short peptide. Subcutaneous injection gives a brief systemic exposure with no mechanism for sustained local concentration inside a muscle, which is the opposite of what the successful preclinical models did.

What the evidence shows

Human data: gene therapy, clearly separated

Becker muscular dystrophy, phase 1/2a. AAV1.CMV.FS344 was delivered by direct bilateral intramuscular quadriceps injection to six patients. Cohort 1 (three patients) received 3 × 10¹¹ vg/kg per leg: two improved on the six-minute walk test by 58 and 125 metres, one showed no change. Cohort 2 received 6 × 10¹¹ vg/kg per leg: two improved by 108 and 29 metres, one did not improve. No adverse effects were encountered. Muscle biopsies showed reduced endomysial fibrosis, reduced central nucleation and a more normal fibre-size distribution, particularly at the higher dose (Mendell 2015).

Sporadic inclusion body myositis. rAAV1.CMV.huFS344 at 6 × 10¹¹ vg/kg was delivered to the quadriceps of both legs in six patients, with an exercise regimen for every participant. Annualised six-minute walk distance improved by 56.0 metres per year in treated subjects against a decline of 25.8 metres per year in eight age-, sex- and baseline-matched untreated subjects (p = 0.01). Four of six treated subjects improved by 58 to 153 metres; two improved minimally, by 5 to 23 metres. Biopsies showed decreased fibrosis and improved regeneration (Mendell 2017).

The rebuttal. A commentary in the same journal argued that the claimed functional improvements attributed to follistatin gene therapy in inclusion body myositis were unfounded (Greenberg 2017). The trial was unblinded, not randomised, used matched untreated comparators rather than concurrent controls, included an exercise programme in the treated group, and had six participants. Anyone citing the positive result should cite the dispute alongside it.

Context from the wider myostatin field. A 2025 review of myostatin inhibition is blunt about the translation problem: despite extensive research and promising preclinical results, clinical trials targeting myostatin in muscular dystrophies have failed to produce substantial improvements in muscle function or fitness, for reasons including drug specificity, species differences in serum myostatin concentrations, and the requirement for neural input for functional gain (Wetzlich 2025).

Human data: injected follistatin protein

None. No trial, no case series with objective endpoints, no pharmacokinetic study.

Animal data, labelled as such

• Transgenic follistatin overexpression in muscle produces dramatic muscle mass increase, comparable to myostatin knockout (Lee 2001).
• AAV1-FS344 injected into cynomolgus macaque quadriceps produced pronounced, durable increases in muscle size and strength, with no abnormal changes in key organs over long-term transgene expression (Kota 2009).

Follistatin gene therapy outside the clinical trial system

A separate thread deserves naming, because people encounter it constantly. A company offering plasmid follistatin gene therapy in Roatán, Honduras, has administered it to self-experimenters including high-profile longevity figures, with coverage in the mainstream business press and a preprint reporting roughly doubled follistatin levels, reduced body fat and a lower epigenetic age marker in 44 participants. Independent analysis has pointed out the obvious: without a control group, results from an uncontrolled 44-person study are not clearly distinguishable from noise, and the protocol has not been through conventional validation or ethical review (Bloomberg, December 2023; Constantin, independent analysis). This is medical tourism with a preprint attached, not evidence, and it is a different thing again from both the AAV trials and injected protein.

Dosing

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

What these numbers are. Short cycles built around a 1 mg vial, with long breaks. There is no pharmacokinetic basis for them, no dose-finding study in any species for injected follistatin protein, and no measured biomarker to titrate against. The honest framing is that the dose equals the vial size divided by the number of days someone decides to run it.

What would make them meaningful. A measured serum follistatin level before and during use, which no protocol includes, plus a functional endpoint. The Roatán preprint at least measured circulating follistatin, which is more than any injectable-protein protocol does.

Technique and reconstitution are in the peptide injection guide.

What people report: what works and what doesn’t

Sources: the aggregated community data set (Peptide Protocol Wiki, 30 reports), the published trials and rebuttal above, and the uncontrolled gene-therapy reporting. Patterns, not proof. Follistatin has the smallest report base in this batch alongside ACE-031.

Reported to work

• Very little, consistently. This is the honest summary and it is unusual enough to put first. The aggregated reports describe outcomes as mixed, with many users finding minimal or no noticeable effect from injectable protein.
• Occasional reports of fullness or a short-term weight increase during a 10 to 20 day block, with no way to distinguish fluid, glycogen and training changes.

Mixed or unclear

• Whether a higher dose helps. Reports describe no additional benefit above about 100 mcg daily, which is consistent with a compound that is not reaching its target in a useful way.
• Isoform identity. The community generally buys FST-344, understands the isoform question poorly, and cannot verify what is in the vial.
• Gene therapy outcomes. The Honduras route produces enthusiastic individual accounts and an uncontrolled preprint. Nothing in it can be verified from outside.

Reported not to work, or disappointing

• The animal-study expectation. The dominant theme in follistatin discussion is the gap between myostatin-knockout imagery and what injectable protein delivers. Aggregated reports describe expectations as inflated by animal results.
• Short cycles producing lasting change. No credible reports of durable gains.
• Side effects: little described beyond injection-site reactions, which again is consistent with minimal systemic exposure rather than a demonstration of safety. The theoretical concerns about activin blockade below have not been assessed in anyone.

What a properly designed trial would need to show: for injected protein, a pharmacokinetic study demonstrating that a subcutaneous dose produces biologically meaningful free follistatin for a meaningful time, followed by a randomised placebo-controlled trial with imaging-based muscle mass and strength. For gene therapy, randomised, blinded trials with concurrent controls, which is exactly what the published rebuttal called for.

Safety and side effects

Gene therapy trials. No adverse effects were encountered in the Becker muscular dystrophy trial (Mendell 2015), and the macaque work found no abnormal changes in key organ morphology or function with long-term transgene expression (Kota 2009). AAV gene therapy carries its own category of risk, including immune responses to capsid and transgene, which is managed in a trial setting and not in a clinic abroad.

Injected protein. No human safety data. No immunogenicity assessment. Follistatin is a glycoprotein, and the glycosylation pattern of a non-pharmaceutical product is unknown and directly relevant to immunogenicity.

Theoretical concerns that follow from the mechanism.

• Activin blockade is not muscle-specific. Follistatin was first characterised as an FSH-suppressing pituitary protein. Activin signalling participates in reproduction, inflammation and glucose regulation, and human data link circulating follistatin to glucose homeostasis (Perakakis 2019). Chronic systemic blockade has not been studied in healthy people.
• Vascular effects of broad TGF-β superfamily inhibition. The ACE-031 programme was halted over epistaxis and telangiectasias attributed to trapping ligands beyond myostatin (Campbell 2017). Follistatin has a different binding profile, but that episode is the reason to take off-target ligand binding seriously rather than dismiss it.
• Tissue growth and malignancy. Removing a growth brake in someone with an undetected tumour is an unquantified risk, and no study addresses it.

Product quality. No pharmaceutical-grade injectable follistatin exists. Producing a correctly folded, correctly glycosylated glycoprotein is beyond peptide synthesis, which makes the identity question sharper here than for a hexapeptide. Surveys of seized peptide products routinely find mislabelled contents (Weber 2017). See peptide sourcing.

Legal and regulatory status

United States. No approved follistatin product in any form. AAV follistatin gene therapy exists only as investigational material under clinical trial regulation. Injectable follistatin protein does not appear in category 1 or 2 of FDA’s 503A bulk drug substance list (updated 14 May 2026), and absence is not authorisation: a bulk substance may be used in 503A compounding only if it meets a statutory condition, which an unapproved recombinant glycoprotein does not. Gene therapy administered outside the US to US residents falls outside FDA oversight entirely, which is the business model of the clinics offering it abroad.

European Union and Germany. No authorisation. Germany’s Anti-Doping Act (AntiDopG) annex lists, under substances that modify myostatin function, “Follistatin und seine Derivate” together with stamulumab. Under § 2(3), acquiring, possessing or importing more than a “non-small quantity” for the purpose of doping in sport is an offence, and the quantity regulation (DmMV, in force 16 March 2023) sets that threshold at 450 mg for follistatin and its derivatives, far above any plausible personal quantity of a 1 mg vial product. The listing itself still means follistatin is treated as a doping substance under German law.

Sport. Prohibited under the WADA list in the hormone and metabolic modulators section, which covers agents preventing activin receptor IIB activation and names myostatin-binding proteins such as follistatin. Detecting an endogenous protein given exogenously is technically difficult, which does not change the prohibition. See peptides and anti-doping rules.

How follistatin fits among myostatin-pathway approaches

The comparison is instructive. ACE-031 showed that this pathway can be moved in humans, with a measured 3.3% increase in lean mass from a single dose, and that broad ligand trapping has vascular consequences serious enough to stop a programme. Bimagrumab showed that receptor-level blockade can increase muscle volume, with its own side-effect profile, and the bimagrumab plus semaglutide work is where this field is actually heading.

Against that, injectable follistatin protein is the weakest member of the family: the most dramatic animal data, the least plausible delivery, and no human measurement of anything. For age-related muscle loss, sarcopenia prevention covers what has evidence behind it.

Related Articles

• ACE-031: The Myostatin Inhibitor That Was Stopped — what happened when this pathway was blocked properly in humans.
• Bimagrumab + Semaglutide: Preserving Muscle While Losing Fat — the activin-receptor approach with real trial data.
• Peptides for Muscle Growth: What the Evidence Actually Supports — the honest hierarchy.
• Sarcopenia Prevention: Preserving Muscle Mass After 40 — the evidence-based approach to age-related muscle loss.
• Peptide Sourcing: Pharmaceutical-Grade vs. Grey Market — why a glycoprotein raises the identity question sharply.